Soleno Therapeutics's total assets for Q1 2026 were $608.39M, an increase of 7.90% from the previous quarter. SLNO total liabilities were $112.59M for the fiscal quarter, a -0.99% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.